Abstract
Autoimmune central nervous system (CNS) inflammation occurs both in a paraneoplastic and non-paraneoplastic context. In a widening spectrum of clinical disorders, the underlying adaptive (auto) immune response targets neurons with a divergent role for cellular and humoral disease mechanisms: (1) in encephalitis associated with antibodies to intracellular neuronal antigens, neuronal antigen-specific CD8+ T cells seemingly account for irreversible progressive neuronal cell death and neurological decline with poor response to immunotherapy. However, a pathogenic effect of humoral immune mechanisms is also debated. (2) In encephalitis associated with antibodies to synaptic and extrasynaptic neuronal cell surface antigens, potentially reversible antibody-mediated disturbance of synaptic transmission and neuronal excitability occurs in the absence of excessive neuronal damage and accounts for a good response to immunotherapy. However, a pathogenic effect of cellular immune mechanisms is also debated. We provide an overview of entities, clinical hallmarks, imaging features, characteristic laboratory, electrophysiological, cerebrospinal fluid and neuropathological findings, cellular and molecular disease mechanisms as well as therapeutic options in these two broad categories of inflammatory CNS disorders.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
The human central nervous system (CNS) can be targeted by aberrant cellular and humoral immune responses, which can either be triggered by systemic infections, and vaccinations (“postinfectious/-vaccinal autoimmune encephalitis”) and a variety of cancers (“paraneoplastic autoimmune encephalitis”) or occur without an (yet) identifiable cause (“non-paraneoplastic autoimmune encephalitis”) [25]. The scope of neurological disorders, in which such misguided adaptive immune responses are directed towards the oligodendrocyte and myelin-sheath is well described [24]. However, in a variety of immune-mediated CNS disorders, neurons seem to be targeted by adaptive cellular and humoral (auto) immune responses of both paraneoplastic and non-paraneoplastic origin [35]. Here, we summarize important clinical phenotypes together with their typical paraclinical measures, putative disease mechanisms, and therapeutic options in this emerging class of inflammatory CNS disorders.
Prerequisites for neuron-directed autoimmunity in the CNS
Antigen-specific cellular and humoral immune responses directed towards CNS neurons are believed to develop as a multi-step process [73]. Soluble or cell-bound neuronal or neuronal-like antigens are engulfed and presented in the context of MHC II and co-stimulatory molecules to CD4+ T cells by professional antigen-presenting cell (APCs) within secondary lymphatic organs (e.g., cervical lymph nodes). This in turn permits CD4+ T cells via cytokine secretion and ligation of CD40 to license APCs to cross-present these antigens in the context of MHC I and co-stimulatory molecules to naive CD8+ T cells, which then become activated and may acquire cytotoxic effector functions (cellular effectors). A lack of such CD4+ T cell help usually results in anergy of CD8+ T cells. Depending on the local cytokine milieu mainly provided by CD4+ T cells, CD8+ T cells with different functional polarization may develop [86]. Tc1 cells are differentiated in the presence of IL-2 and IL-12, which induce the transcription factor T-bet. They produce IFN-γ and TNF-α and exert strong cytotoxicity. Tc2 cells are differentiated in the presence of IL-4, which induces the transcription factor GATA-3. They produce IL-4, IL-5, and IL-13 and exert a less robust cytotoxicity. Tc17 cells are differentiated in the presence of TGF-β and IL-6, which mainly induce the transcription factor RORγt. They produce IL-17 and have been reported to exert only weak cytotoxicity.
Naive B cells produce both IgM (and IgD) that are anchored in their plasma membrane and function as BCRs [48]. Naive B cells that encounter, ingest, and present their cognate so-called “thymus-dependent (TD) antigen” in the context of MHC II and co-stimulatory molecules to CD4+ T cells are in turn activated via cytokine secretion and ligation of CD40 and become antibody-secreting plasma cells (humoral effectors). Thereby, B cells can further diversify their Ig-genes by two DNA-modifying mechanisms [48]; somatic hypermutation and class switch recombination generate highly specific and adapted humoral responses. Somatic hypermutation introduces in a transcription-dependent manner non-templated point mutations in the variable (V) region of Ig genes, thereby enabling the selection of antibodies with increased affinity for the antigen. In contrast, class switch recombination modulates antibody effector function by replacing one constant (C) region with another, while retaining the binding specificity of the BCR. Depending on the cytokine milieu mainly provided by the CD4+ T cells, activated B cells undergo antibody class switching to produce IgG, IgA, or IgE antibodies [48]. Switch to IgG1 and IgG3 promoting complement activation and antibody-mediated cellular cytotoxicity by NK cells occurs in the presence of IFN-γ. In contrast, switch to IgG2, IgG4, and IgA promoting antigen-neutralizing effects occurs in the presence of IL-4 and IL-5. Although some pathogen-derived “thymus-independent (TI) antigens” may induce somatic hypermutation and class switch recombination in B cells independent from CD4+ T cell help, a lack of such help usually results in persistent secretion of complement-activating IgM (and IgD; [48]).
Following peripheral activation, both antibody-secreting plasma cells and cytotoxic CD8+ T cells (together with CD4+ T cells) may enter the CNS to attack neurons and cause functional and structural impairment [69, 97]. Moreover, under such inflammatory conditions, even antibodies produced in the periphery may permeate the blood–brain barrier (BBB) by various paracellular and transcellular mechanisms and thus contribute to neuron-directed immunity, whereas under physiological conditions, the BBB is usually impermeable for antibodies [23] (see Fig. 1).
In general, both effector arms of the adaptive immune response may be activated irrespective of the cellular localization of the neuronal antigen or its antigenic epitope (plasma membrane vs. interior cellular compartments). In terms of relevant effector mechanisms, plasma cell-derived antibodies usually recognize discontinuous conformational epitopes composed of segments of the respective neuronal plasma membrane protein antigen that are brought together in its three-dimensional structure and exposed on the neuronal plasma membrane. Antibodies may thus specifically impact the function and expression of theses antigens. Whether antibodies may also bind to and impact the function or expression of intracellular neuronal antigens, either by passive uptake into the neuron or by active binding to intracellular antigens that are transiently exposed to the plasma membrane is currently a matter of debate [30, 96]. Moreover, peptides derived from both intracellular and plasma membrane neuronal antigens might potentially be recognized by antibodies when exposed on the surface membrane in complex with MHC I molecules, although this is usually performed by CD8+ T cells.
Cytotoxic CD8+ T cells usually recognize continuous linear peptide epitopes consisting of 8–10 amino acids that are derived from intracellular neuronal proteins by extensive antigen processing and presented in the context of MHC I molecules on the cell surface membrane. Whether peptides derived from neuronal surface membrane antigens are also presented to cytotoxic CD8+ T cells in the context of MHC I molecules is unclear at present. In both cases, CD8+ T cells cannot directly impact the function or expression of their cognate antigens, but recognize their expression by the respective neuron. This enables them to contribute to neuronal dysfunction and cell death by the antigen-dependent release of effector molecules (perforin, granzymes) from cytotoxic granules. Indeed, we could show that two separate functional consequences result from a direct cell-to-cell contact between antigen-presenting neurons and antigen-specific CD8+ T cells. (1) An immediate impairment of electrical signaling in single neurons and neuronal networks occurs as a result of massive shunting of the membrane capacitance after insertion of channel-forming perforin (and probably activation of other transmembrane conductances), which is paralleled by an increase of intracellular Ca2+ levels. (2) Antigen-dependent neuronal apoptosis may occur independently of perforin and members of the granzyme B cluster, suggesting that extracellular effects can substitute for intracellular delivery of granzymes by perforin. Thus, electrical silencing is an immediate consequence of MHC I-restricted interaction of CD8+ T cells with neurons. Of course, these changes in neuronal excitability are not induced specifically in response to a certain antigen, but apply to all antigen-presenting neurons encountered by activated cytotoxic CD8+ T cells [69, 71].
Paraneoplastic autoimmune encephalitis is probably mediated by cytotoxic CD8+ T cells specific for intracellular neuronal antigens
An ever-growing number of paraneoplastic CNS disorders are defined by the presence of IgG antibodies in the serum and CSF directed against intracellular neuronal antigens aberrantly expressed also by tumor cells (“onco-neuronal antibodies”) [67]. These tumors often contain neuronally differentiated tissue (germ cell tumors), express certain neuroendokrine peptides (SCLC, neuroblastoma), or occur in organs with a role in immune regulation (thymoma). However, due to the intracellular localization of the antigens, the humoral immune response is considered a non-pathogenic “epiphenomenon” solely indicating neuron-directed immunity and defining its antigen. In contrast, a variety of findings suggest a pathogenic role of cytotoxic CD8+ T cells for neuronal damage in these disorders: (1) neuronal damage often correlates with the number of CD8+ T cells, (2) CD8+ T cells are found in the CNS parenchyma in close spatial proximity to neuronal target cells, (3) CD8+ T cells show an activated phenotype with substantial expression of the effector molecules (perforin and granzymes) in cytotoxic granules with a polar orientation towards the target cell membrane, (4) CD8+ T cells stain positive for CD107 indicating recent exocytosis of cytotoxic granules (i.e., degranulation), (5) neuronal target cells exhibit substantial cell surface expression of MHC I molecules allowing for cognate antigen-recognition by CD8+ T cells, (6) CD8+ T cells exhibit a restricted T cell receptor (TCR) repertoire (i.e., oligoclonal expansions) suggesting that they have expanded from a few precursors locally responding to a distinct neuronal antigen [6, 69]. These criteria, however, have not yet been demonstrated entirely for all entities.
In clinical terms, inflammatory CNS disorders associated with IgG antibodies against intracellular neuronal antigens are characterized by a multifocal presentation of CNS-related symptoms involving the neocortex, the limbic system, basal ganglia, brainstem, cerebellum, and spinal cord as well as PNS-related symptoms involving radices, plexus, and peripheral nerves in a variable extent (Table 1). The clinical presentation partially reflects the pattern of expression of the respective neuronal antigen: ANNA-1 targets nuclear ELAVL (“Hu”) proteins expressed in central and peripheral neurons, and the corresponding clinical syndrome typically includes CNS and PNS manifestations [58]. In contrast, ANNA-2 targets nuclear NOVA-1 and -2 (“Ri”) proteins expressed in central, but not peripheral neurons and the clinical syndrome is usually restricted to the CNS [75] (Table 1). MRI findings include T2/FLAIR hyperintense, occasionally contrast-enhancing lesions in the cortex, medial temporal lobes, basal ganglia, brainstem, cerebellum, and spinal cord. Inflammatory changes are usually found in CSF studies including lymphocytic pleocytosis, mildly elevated protein together with intrathecal IgG synthesis and oligoclonal bands, but normal glucose and lactate levels [19]. The disease entities usually exhibit a chronic progressive clinical course and poor response to immunotherapy, especially to antibody-depleting therapies. Even successful removal of the tumor considered to drive the pathogenic immune response is usually not associated with disease amelioration [19].
However, there exists a group of CNS disorders with antibodies against intracellular neuronal antigens located mainly at presynaptic (GAD65) or postsynaptic (GABARAP, Gephyrin) sites of inhibitory GABAergic and glycinergic synapses, which less frequently associate with tumors. In these entities, there is often no evidence for cellular or humoral neuronal cytotoxicity, although some patients show neuroaxonal swelling, chromatolysis and vacuolization of neurons, microglial proliferation, as well as infiltration and apposition of cytotoxic CD8+ T cells to neurons [6, 40]. Further, there are reports of potentially pathogenic humoral mechanisms probably targeting inhibitory CNS neuronal networks in anti-GAD encephalitis [29, 57, 61], but until now the specificity of possible pathogenic antibodies has not been elucidated. These findings together with the wide spectrum of clinical presentations suggest that anti-GAD encephalitis comprises of a quite heterogenous group of CNS disorders with regard to their etiologies and disease mechanisms.
Paraneoplastic and non-paraneoplastic autoimmune encephalitis is probably mediated by antibodies to neuronal surface membrane antigens
Autoimmune inflammatory CNS disorders associated with IgG antibodies in the serum and CSF directed against neuronal surface membrane antigens [54, 97] occur both in a paraneoplastic and non-paraneoplastic context. Tumors assumed to drive the pathogenic immune response usually contain neuronally differentiated tissue expressing the respective neuronal antigen or occur in organs with a role in immune regulation, such as the thymus.
Antibodies bind to synaptic and extra-synaptic ligand- and voltage-gated ion channels (Table 2) involved in excitatory (AMPA-, NMDA-, mGluR1-, mGluR5-, and nAch-receptors, VGCC, VGKC) and inhibitory (GABAB- and Glycine-receptors, VGKC) synaptic transmission and plasticity. Moreover, these antibodies also target neuronal membrane proteins implicated in clustering of voltage-gated potassium channels inside the synapse [leucine-rich glioma-inactivated 1 (LGI1)] or outside the synapse at the juxtaparanodal region of the node of Ranvier [contactin-2 and contactin-associated protein-like 2 (CASPR2)] thereby indirectly impacting neuronal excitability.
In principle, depending on the IgG subtype, antibodies may (1) specifically activate or block the function of their target molecules (GABAB-, Glycine- nAch-receptors, VGCC, VGKC), (2) crosslink and internalize the receptors (AMPA- and NMDA-receptors), (3) activate the complement cascade with subsequent formation of the terminal membrane attack complex and target cell lysis (probably mGluR1/5 receptors, VGCC, VGKC) and (4) activate Fc-receptors with subsequent antibody-dependent cell-mediated cytotoxicity (ADCC) mainly by NK cells [23]. However, the effector mechanisms involved in the pathogenic effect of the autoantibodies within the CNS are not yet fully understood. In fact, autoantibodies in anti-NMDA-R and -AMPA-R, GABAB-R encephalitis are of the IgG1 and IgG3 type and are thus capable of activating complement in the presence of patient plasma (containing high concentrations of complement factors). However, in none of the reported autopsy or biopsy studies complement depositions could be detected on neurons suggesting that in the presence of patient CSF (containing low concentrations of complement factors) these IgG 1 and 3 autoantibodies do not lead to relevant complement activation [6, 32, 47, 50, 63, 93]. In contrast, autoantibodies in VGKC-complex encephalitis are predominantly of the IgG4 (and IgG1) type and thus are unable to activate complement in the presence of patient plasma. However, in the only biopsy study reported thus far, complement depositions could be detected on neurons in VGKC-complex encephalitis suggesting that in the presence of patient CSF these IgG4 (or the IgG1) autoantibodies are capable of activating complement [6]. These conflicting results suggest that effector mechanisms of distinct autoantibody classes and subtypes may differ between the CNS and peripheral organs.
Moreover, with the growing clinical awareness of the autoantibodies and improved diagnostic possibilities due to cell-based detection systems more patients are currently identified with persisting IgM antibodies without subsequent class switch to IgG and rarely with IgA antibodies against neuronal plasma membrane antigens [78]. This class-diversity of the neuron-directed adaptive humoral immune response in CNS may indeed reflect different milieus (e.g., absence or presence of different tumors), in which B cell activation takes place. Moreover, lack of class switch might indicate insufficient CD4+ T cell-mediated help in B cell activation. However, these issues need further experimental investigation. Further, it remains to be determined, whether cytotoxicity by CD8+ T cells contributes to functional and structural neuronal impairment.
Inflammatory CNS disorders associated with IgG antibodies against neuronal surface membrane antigens are characterized by a presentation of CNS- and sometimes PNS-related clinical symptoms representing the expression distribution and function of the respective target antigen [54, 97]. On cerebral MRI cortical and subcortical gray matter regions may display mild and often transient T2/FLAIR hyperintense signals. CSF findings may initially be normal, but often include inflammatory changes (lymphocytic pleocytosis, mildly elevated protein, intrathecal IgG synthesis with oligoclonal bands, but normal glucose and lactate levels). The clinical course is usually either monophasic or relapsing-remitting, but rarely progressive and clinical symptoms and paraclinical measures usually display a good response to immunotherapy, especially to antibody-depleting therapies. Upon detection of a tumor, sufficient tumor therapy is crucial to halt the pathogenic immune response [54, 97].
It should be noted that antibody-mediated autoimmunity to non-neuronal ion channels on the cell surface membrane [aquaporin 4 [74] on astrocytes (and neurons), Na(x) channel [38] on ependymal cells, astrocytes, and pituicytes (circumventricular organs)] may occur also in a paraneoplastic context (neuromyelitis optica: breast cancer, Hürthle cell thyroid carcinoma, carcinoid, pituitary somatotropinoma, B cell lymphoma, monoclonal gammopathy [74]; essential hypernatremia [38]: ganglioneuroma).
Conclusions
A growing number of immune-mediated CNS disorders of paraneoplastic and non-paraneoplastic autoimmune origin have recently emerged, in which neurons are the target of both adaptive cellular and humoral immune responses. In autoimmune encephalitis associated with antibodies to neuronal surface membrane antigens, potentially reversible mechanisms of antibody-mediated impairment of synaptic transmission and neuronal excitability prevail. Hence, these disorders offer unique insight and provoke further investigation into the consequences of immune-mediated disruption of distinct neuronal signaling pathways within the living CNS.
In contrast, paraneoplastic autoimmune encephalitis associated with antibodies to intracellular neuronal antigens seems to be mediated by cytotoxic CD8+ T cells that cause functional and structural neuronal impairment in a way not specific for the respective antigen.
References
Alamowitch S, Graus F, Uchuya M, Rene R, Bescansa E, Delattre JY (1997) Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain 120(Pt 6):923–928
Antoine JC, Honnorat J, Camdessanche JP, Magistris M, Absi L, Mosnier JF, Petiot P, Kopp N, Michel D (2001) Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 49:214–221
Baker SK, Morillo C, Vernino S (2009) Autoimmune autonomic ganglionopathy with late-onset encephalopathy. Auton Neurosci 146:29–32
Becker EB, Zuliani L, Pettingill R, Lang B, Waters P, Dulneva A, Sobott F, Wardle M, Graus F, Bataller L, Robertson NP, Vincent A (2012) Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry 83:437–440
Bernal F, Shams’ili S, Rojas I, Sanchez-Valle R, Saiz A, Dalmau J, Honnorat J, Sillevis Smitt P, Graus F (2003) Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease. Neurology 60:230–234
Bien CG, Vincent A, Barnett MH, Becker AJ, Blumcke I, Graus F, Jellinger KA, Reuss DE, Ribalta T, Schlegel J, Sutton I, Lassmann H, Bauer J (2012) Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 135:1622–1638
Boronat A, Sabater L, Saiz A, Dalmau J, Graus F (2011) GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 76:795–800
Briani C, Vitaliani R, Grisold W, Honnorat J, Graus F, Antoine JC, Bertolini G, Giometto B (2011) Spectrum of paraneoplastic disease associated with lymphoma. Neurology 76:705–710
Bruylant K, Crols R, Humbel RL, Appel B, De Deyn PP (2006) Probably anti-Tr associated paraneoplastic cerebellar degeneration as initial presentation of a squamous cell carcinoma of the lung. Clin Neurol Neurosurg 108:415–417
Butler MH, Hayashi A, Ohkoshi N, Villmann C, Becker CM, Feng G, De Camilli P, Solimena M (2000) Autoimmunity to gephyrin in stiff-man syndrome. Neuron 26:307–312
Carr I (1982) The Ophelia syndrome: memory loss in Hodgkin’s disease. Lancet 1:844–845
Chan KH, Vernino S, Lennon VA (2001) ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 50:301–311
Coesmans M, Smitt PA, Linden DJ, Shigemoto R, Hirano T, Yamakawa Y, van Alphen AM, Luo C, van der Geest JN, Kros JM, Gaillard CA, Frens MA, de Zeeuw CI (2003) Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies. Ann Neurol 53:325–336
Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, Lam BL, Lennon VA (2003) Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 54:38–50
Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7:1091–1098
Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, Saiz A, Meneses P, Rosenfeld MR (2004) Clinical analysis of anti-Ma2-associated encephalitis. Brain 127:1831–1844
Dalmau J, Gultekin SH, Voltz R, Hoard R, DesChamps T, Balmaceda C, Batchelor T, Gerstner E, Eichen J, Frennier J, Posner JB, Rosenfeld MR (1999) Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 122(Pt 1):27–39
Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R (2011) Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10:63–74
Dalmau J, Rosenfeld MR (2008) Paraneoplastic syndromes of the CNS. Lancet Neurol 7:327–340
Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR (2007) Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61:25–36
De Camilli P, Thomas A, Cofiell R, Folli F, Lichte B, Piccolo G, Meinck HM, Austoni M, Fassetta G, Bottazzo G et al (1993) The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of stiff-man syndrome with breast cancer. J Exp Med 178:2219–2223
de Graaff E, Maat P, Hulsenboom E, van den Berg R, van den Bent M, Demmers J, Lugtenburg PJ, Hoogenraad CC, Sillevis Smitt P (2012) Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 71(6):815–824
Diamond B, Huerta PT, Mina-Osorio P, Kowal C, Volpe BT (2009) Losing your nerves? Maybe it’s the antibodies. Nat Rev Immunol 9:449–456
Eckstein C, Saidha S, Levy M (2011) A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. J Neurol 259(5):801–816
Flanagan EP, Caselli RJ (2011) Autoimmune encephalopathy. Semin Neurol 31:144–157
Folli F, Solimena M, Cofiell R, Austoni M, Tallini G, Fassetta G, Bates D, Cartlidge N, Bottazzo GF, Piccolo G et al (1993) Autoantibodies to a 128-kD synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 328:546–551
Fukuda T, Motomura M, Nakao Y, Shiraishi H, Yoshimura T, Iwanaga K, Tsujihata M, Eguchi K (2003) Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert–Eaton myasthenic syndrome. Ann Neurol 53:21–28
Furneaux HM, Rosenblum MK, Dalmau J, Wong E, Woodruff P, Graus F, Posner JB (1990) Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 322:1844–1851
Geis C, Weishaupt A, Grunewald B, Wultsch T, Reif A, Gerlach M, Dirkx R, Solimena M, Perani D, Heckmann M, Toyka KV, Folli F, Sommer C (2011) Human stiff-person syndrome IgG induces anxious behavior in rats. PLoS ONE 6:e16775
Geis C, Weishaupt A, Hallermann S, Grunewald B, Wessig C, Wultsch T, Reif A, Byts N, Beck M, Jablonka S, Boettger MK, Uceyler N, Fouquet W, Gerlach M, Meinck HM, Siren AL, Sigrist SJ, Toyka KV, Heckmann M, Sommer C (2010) Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 133:3166–3180
Gibbons CH, Centi J, Vernino S, Freeman R (2012) Autoimmune autonomic ganglionopathy with reversible cognitive impairment. Arch Neurol 69:461–466
Graus F, Boronat A, Xifro X, Boix M, Svigelj V, Garcia A, Palomino A, Sabater L, Alberch J, Saiz A (2010) The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 74:857–859
Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, Escaramis G, Delattre JY (2001) Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 124:1138–1148
Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A (2002) P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 59:764–766
Graus F, Saiz A, Dalmau J (2010) Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 257:509–517
Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang B, Dalmau J (2005) Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 165:166–171
Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J (2000) Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123(Pt 7):1481–1494
Hiyama TY, Matsuda S, Fujikawa A, Matsumoto M, Watanabe E, Kajiwara H, Niimura F, Noda M (2010) Autoimmunity to the sodium-level sensor in the brain causes essential hypernatremia. Neuron 66:508–522
Hoffmann LA, Jarius S, Pellkofer HL, Schueller M, Krumbholz M, Koenig F, Johannis W, la Fougere C, Newman T, Vincent A, Voltz R (2008) Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry 79:767–773
Holmoy T, Skorstad G, Roste LS, Scheie D, Alvik K (2009) Stiff-person syndrome associated with lower motor neuron disease and infiltration of cytotoxic T cells in the spinal cord. Clin Neurol Neurosurg 111:708–712
Honnorat J, Aguera M, Zalc B, Goujet C, Quach T, Antoine JC, Belin MF (1998) POP66, a paraneoplastic encephalomyelitis-related antigen, is a marker of adult oligodendrocytes. J Neuropathol Exp Neurol 57:311–322
Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF (1996) Antibodies to a subpopulation of glial cells and a 66-kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 61:270–278
Honnorat J, Byk T, Kusters I, Aguera M, Ricard D, Rogemond V, Quach T, Aunis D, Sobel A, Mattei MG, Kolattukudy P, Belin MF, Antoine JC (1999) Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes. Eur J Neurosci 11:4226–4232
Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, Parsons TD, Lynch DR, Dalmau J, Balice-Gordon RJ (2010) Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 30:5866–5875
Hutchinson M, Waters P, McHugh J, Gorman G, O’Riordan S, Connolly S, Hager H, Yu P, Becker CM, Vincent A (2008) Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 71:1291–1292
Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A (2010) Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 133:2734–2748
Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, Friese MA, Galea I, Kullmann DM, Beeson D, Lang B, Bien CG, Vincent A (2010) N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 133:1655–1667
Janeway CA, Travers P, Walport M, Shlomchik MJ (2001) Immunobiology: the immune system in health and disease. vol 5. Garland Science, New York
Keime-Guibert F, Graus F, Broet P, Rene R, Molinuevo JL, Ascaso C, Delattre JY (1999) Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology 53:1719–1723
Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, Mata S, Kremens D, Vitaliani R, Geschwind MD, Bataller L, Kalb RG, Davis R, Graus F, Lynch DR, Balice-Gordon R, Dalmau J (2009) AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 65:424–434
Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, Cowell JK, Dalmau J (2010) Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 9:776–785
Lancaster E, Huijbers MG, Bar V, Boronat A, Wong A, Martinez-Hernandez E, Wilson C, Jacobs D, Lai M, Walker RW, Graus F, Bataller L, Illa I, Markx S, Strauss KA, Peles E, Scherer SS, Dalmau J (2011) Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 69:303–311
Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, Friedman D, Skeen MB, Grisold W, Kimura A, Ohta K, Iizuka T, Guzman M, Graus F, Moss SJ, Balice-Gordon R, Dalmau J (2010) Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 9:67–76
Lancaster E, Martinez-Hernandez E, Dalmau J (2011) Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 77:179–189
Lancaster E, Martinez-Hernandez E, Titulaer MJ, Boulos M, Weaver S, Antoine JC, Liebers E, Kornblum C, Bien CG, Honnorat J, Wong S, Xu J, Contractor A, Balice-Gordon R, Dalmau J (2011) Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 77:1698–1701
Lennon VA, Kryzer TJ, Griesmann GE, O’Suilleabhain PE, Windebank AJ, Woppmann A, Miljanich GP, Lambert EH (1995) Calcium-channel antibodies in the Lambert–Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 332:1467–1474
Levy LM, Levy-Reis I, Fujii M, Dalakas MC (2005) Brain gamma-aminobutyric acid changes in stiff-person syndrome. Arch Neurol 62:970–974
Lucchinetti CF, Kimmel DW, Lennon VA (1998) Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 50:652–657
Luque FA, Furneaux HM, Ferziger R, Rosenblum MK, Wray SH, Schold SC Jr, Glantz MJ, Jaeckle KA, Biran H, Lesser M et al (1991) Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 29:241–251
Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG (2010) Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 67:470–478
Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J (2007) Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol 61:544–551
Marignier R, Chenevier F, Rogemond V, Sillevis Smitt P, Renoux C, Cavillon G, Androdias G, Vukusic S, Graus F, Honnorat J, Confavreux C (2010) Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol 67:627–630
Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, Sangha N, Martinez-Lage M, Dalmau J (2011) Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 77:589–593
Mas N, Saiz A, Leite MI, Waters P, Baron M, Castano D, Sabater L, Vincent A, Graus F (2011) Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 82:1399–1401
Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, Valldeoriola F, Antoine JC, Rosenblum MK, Rosenfeld MR, Newsom-Davis J, Posner JB, Dalmau J (1997) Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert–Eaton myasthenic syndrome. Brain 120(Pt 8):1279–1300
McKeon A, Lennon VA, Lachance DH, Fealey RD, Pittock SJ (2009) Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. Arch Neurol 66:735–741
McKeon A, Pittock SJ (2011) Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol 122:381–400
McKeon A, Tracy JA, Pittock SJ, Parisi JE, Klein CJ, Lennon VA (2011) Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond. Arch Neurol 68:1282–1289
Melzer N, Meuth SG, Wiendl H (2009) CD8 + T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability. FASEB J 23:3659–3673
Melzer N, Meuth SG, Wiendl H (2012) Neuron-directed autoimmunity in the central nervous system: entities, mechanisms, diagnostic clues, and therapeutic options. Curr Opin Neurol 25:341–348
Meuth SG, Herrmann AM, Simon OJ, Siffrin V, Melzer N, Bittner S, Meuth P, Langer HF, Hallermann S, Boldakowa N, Herz J, Munsch T, Landgraf P, Aktas O, Heckmann M, Lessmann V, Budde T, Kieseier BC, Zipp F, Wiendl H (2009) Cytotoxic CD8 + T cell-neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death. J Neurosci 29:15397–15409
Moscato EH, Jain A, Peng X, Hughes EG, Dalmau J, Balice-Gordon RJ (2010) Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. Eur J Neurosci 32:298–309
Pedemonte E, Mancardi G, Giunti D, Corcione A, Benvenuto F, Pistoia V, Uccelli A (2006) Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases. Pharmacol Ther 111:555–566
Pittock SJ, Lennon VA (2008) Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 65:629–632
Pittock SJ, Lucchinetti CF, Lennon VA (2003) Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 53:580–587
Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, Kim KK, Kilimann MW, Lennon VA (2005) Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 58:96–107
Pittock SJ, Yoshikawa H, Ahlskog JE, Tisch SH, Benarroch EE, Kryzer TJ, Lennon VA (2006) Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 81:1207–1214
Pruss H, Holtje M, Maier N, Gomez A, Buchert R, Harms L, Ahnert-Hilger G, Schmitz D, Terborg C, Kopp U, Klingbeil C, Probst C, Kohler S, Schwab JM, Stoecker W, Dalmau J, Wandinger KP (2012) IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology 78:1743–1753
Psimaras D, Carpentier AF, Rossi C (2010) Cerebrospinal fluid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry 81:42–45
Raju R, Rakocevic G, Chen Z, Hoehn G, Semino-Mora C, Shi W, Olsen R, Dalakas MC (2006) Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain 129:3270–3276
Rojas I, Graus F, Keime-Guibert F, Rene R, Delattre JY, Ramon JM, Dalmau J, Posner JB (2000) Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 55:713–715
Rosenfeld MR, Eichen JG, Wade DF, Posner JB, Dalmau J (2001) Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 50:339–348
Sadeghian H, Vernino S (2010) Progress in the management of paraneoplastic neurological disorders. Ther Adv Neurol Disord 3:43–52
Saiz A, Blanco Y, Sabater L, Gonzalez F, Bataller L, Casamitjana R, Ramio-Torrenta L, Graus F (2008) Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 131:2553–2563
Shams’ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, Vecht C, Sillevis Smitt P (2003) Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 126:1409–1418
Shrikant PA, Rao R, Li Q, Kesterson J, Eppolito C, Mischo A, Singhal P (2010) Regulating functional cell fates in CD8 T cells. Immunol Res 46:12–22
Sillevis Smitt P, Grefkens J, de Leeuw B, van den Bent M, van Putten W, Hooijkaas H, Vecht C (2002) Survival and outcome in 73 anti-Hu-positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 249:745–753
Sillevis Smitt P, Kinoshita A, De Leeuw B, Moll W, Coesmans M, Jaarsma D, Henzen-Logmans S, Vecht C, De Zeeuw C, Sekiyama N, Nakanishi S, Shigemoto R (2000) Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 342:21–27
Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P (1990) Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 322:1555–1560
Solimena M, Folli F, Denis-Donini S, Comi GC, Pozza G, De Camilli P, Vicari AM (1988) Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 318:1012–1020
Sommer C, Weishaupt A, Brinkhoff J, Biko L, Wessig C, Gold R, Toyka KV (2005) Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 365:1406–1411
Tschernatsch M, Gross O, Kneifel N, Kaps M, Blaes F (2009) SOX-1 autoantibodies in patients with paraneoplastic neurological syndromes. Autoimmun Rev 8:549–551
Tuzun E, Zhou L, Baehring JM, Bannykh S, Rosenfeld MR, Dalmau J (2009) Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol 118:737–743
Vernino S, Lennon VA (2000) New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 47:297–305
Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA (2000) Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 343:847–855
Vincent A (2010) Successful ‘passive transfer’ of paraneoplastic stiff person syndrome with antibodies to an intracellular antigen. Brain 133:3164–3165
Vincent A, Bien CG, Irani SR, Waters P (2011) Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 10:759–772
Voltz R, Gultekin SH, Rosenfeld MR, Gerstner E, Eichen J, Posner JB, Dalmau J (1999) A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 340:1788–1795
Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA (2001) CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49:146–154
Zhang Q, Tanaka K, Sun P, Nakata M, Yamamoto R, Sakimura K, Matsui M, Kato N (2012) Suppression of synaptic plasticity by cerebrospinal fluid from anti-NMDA receptor encephalitis patients. Neurobiol Dis 45:610–615
Acknowledgments
Scientific and clinical work of the authors is supported by the German research foundation (DFG), the BMBF, the IZKF Münster, the IMF Münster, and industry.
Conflicts of interest
All authors declare no relevant conflicts of interest. N.M. has received honoraria for lecturing and travel expenses for attending meetings from Biogen Idec, GlaxoSmithKline, and Fresenius Medical Care. S.G.M. has received honoraria for lecturing and travel expenses for attending meetings and has received financial research support from Bayer, Biogen Idec, Sanofi-Aventis, Bayer Schering, Novo Nordisk, Merck Serono Novartis, and Teva. H.W. has received funding for travel and speaker honoraria from Bayer Schering Pharma, Biogen Idec/Elan Corporation, Sanofi-Aventis, Merck Serono, and Teva Pharmaceutical Industries Ltd.; has served/serves as a consultant for Merck Serono, Medac, Inc., Sanofi-Aventis/Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Novartis, and Novo Nordisk, and receives research support from Bayer Schering Pharma, Biogen Idec/Elan Corporation, Sanofi-Aventis, Merck Serono, and Novo Nordisk.
Open Access
This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Melzer, N., Meuth, S.G. & Wiendl, H. Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system. J Neurol 260, 1215–1233 (2013). https://doi.org/10.1007/s00415-012-6657-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-012-6657-5